Description: Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.
Home Page: www.longeveron.com
LGVN Technical Analysis
1951 NW 7th Avenue
Miami,
FL
33136
United States
Phone:
305 909 0840
Officers
| Name | Title |
|---|---|
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Chairman |
| Mr. James Clavijo CPA | CFO & Treasurer |
| Mr. Paul T. Lehr J.D. | International Exec. Director, Gen. Counsel & Sec. |
| Dr. Kwan-Hong Min M.D., Ph.D. | Chief Medical Officer & Interim CEO |
| Dr. Dan Gincel Ph.D. | Sr. VP of Strategic Collaborations & Scientific Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8691 |
| Price-to-Sales TTM: | 51.5031 |
| IPO Date: | 2021-02-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 18 |